Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
George Medicines Files NDA with FDA for Triple Combination Therapy for Hypertension
Details : GMRx2 is a triple combination of telmisartan, amlodipine and indapamide, in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Teva UK and Closed Loop Medicine Announce Strategic Partnership for Personalised Medicines
Details : Teva will use Closed Loop Medicine’s SaMD platform for personalized chronic disorder treatments like CLM-HT01.
Brand Name : CLM-HT01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 26, 2024
Lead Product(s) : Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhag...
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 12, 2023
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2022
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bisoprolol Fumarate,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).
Brand Name : Biramlo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 19, 2022
Lead Product(s) : Bisoprolol Fumarate,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Amlodipine,Olmesartan Medoxomil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Divestment
Details : The agreement outlines a transition period during which Daiichi Sankyo and Cosette will transfer responsibilities for the manufacture and commercialization of Azor, Benicar, Effient and other products, including quality assurance, pharmacovigilance and r...
Brand Name : Azor
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 18, 2022
Lead Product(s) : Amlodipine,Olmesartan Medoxomil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2021
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amlodipine,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Viatris
Deal Size : $12,000.0 million
Deal Type : Merger
Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan
Details : Pfizer and Mylan have received clearance from the US FTC to advance the merger of Pfizer’s Upjohn generics unit and Mylan. As part of the FTC clearance, the companies need to divest seven products before moving forward with the merger, this includes Up...
Brand Name : Caduet
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2020
Lead Product(s) : Amlodipine,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Viatris
Deal Size : $12,000.0 million
Deal Type : Merger
LOOKING FOR A SUPPLIER?